To evaluate the overall results of beta-blockers in heart failure.
Methods of synthesis
How were the studies combined?
The combined effect was estimated by weighting the result of each individual trial by the reciprocal of its variance. Fixed-effect or random-effects models were used, according to whether the test of heterogeneity was significant.
How were differences between studies investigated?
A chi-squared test was used to assess heterogeneity. Subgroup and sensitivity analyses were conducted. The robustness of the results of the meta-analysis was assessed by estimating how many trials with a neutral effect were required to produce a non significant result.
Results of the review
Eighteen randomised controlled trials (1,305 patients in the placebo group and 1,718 patients treated with betablockers) were included.
All-cause mortality was lower in the beta-blocker group than in the placebo group: 7.5% versus 11.9 (pooled odds ratio 0.68, 95% confidence interval: 0.53, 0.88). However, this effect was moderately robust and varied according to the type of beta-blocker tested. The reduction of mortality risk was greater for nonselective beta-blockers than for beta1-selective agents. Beta-blockade increased the ejection fraction by 29% and reduced the combined risk of death or hospitalisation for heart failure by 37% (p<0.001). Both effects remained significant even if more than 90% of the trials were eliminated from the analysis, or if a large number of trials with a neutral result were added to the analysis. The effect of beta-blockade on NYHA functional class was of borderline significance (p=0.04) and disappeared with the addition or removal of only one moderate-size study.
